Recombinant Human Interferon ?1b 30??g Original wholesale comparison
$1.00
Recombinant Human Interferon ?1b (brand: Yundesu®), produced by Beijing Sanyuan Gene Pharmaceutical Co., Ltd., is a lyophilized polypeptide used in immunology and antiviral preclinical research. Each vial contains 30??g of non-glycosylated IFN-?1b. Approved in China under NMPA Registration S19990034 and standard code 86900115000011.
?? Strictly for laboratory research use only.?Please consult the staff for other purposes?
描述
Recombinant Human Interferon ?1b Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Recombinant Human Interferon ?1b Injection (Yundesu®) |
| Generic Name | Interferon ?1b, recombinant |
| CAS Number | 175061?16?4 |
| Molecular Formula | 166 amino acid polypeptide (no glycosylation) |
| Molecular Weight | ~19.4?kDa |
| Dosage Form | Lyophilized powder for injection |
| Strength | 30??g per vial |
| Pack Size | 1 vial per box |
| Approval Number | S19990034 (China NMPA) |
| Product Code | 86900115000011 |
| Manufacturer | Beijing Sanyuan Gene Pharmaceutical Co., Ltd. |
| Barcode | 6924520520005 |
| Storage | Store at –20?°C; avoid freeze–thaw cycles |
| Intended Use | Laboratory research only |
Recombinant Human Interferon ?1b Mechanism of Action
Recombinant IFN-?1b is a type I interferon produced in E. coli that binds the IFNAR receptor, activating the JAK?STAT pathway. This triggers transcription of antiviral and immunomodulatory genes, leading to inhibition of viral replication, activation of NK cells, and suppression of tumor cell proliferation.
Research Applications & Pharmacology
-
Antiviral models: Effective in SARS-CoV?2, RSV, and chronic Hepatitis B research
-
Oncology immunostimulant: Used in studies of tumor immunotherapy and hematologic malignancies
synapse.patsnap.com+11frontiersin.org+11cancer.gov+11 -
Mechanistic assays: Ideal for gene expression, PK/PD, and signal pathway studies
-
Pharmacokinetics: Polypeptide, dosage/timing vary; use sterile preparation per protocol
Safety Profile & Handling
Preclinical observations:
-
Possible transient fever, malaise, injection-site reactions
-
Typically low toxicity in animal models at researched dosages
Lab precautions:
-
Use full sterile technique (PBS reconstitution)
-
Use personal protective equipment (PPE) when handling vials
-
Monitor immune markers or body temperature in animal studies
-
Treat as bioactive protein; avoid inhalation, ingestion, or skin contact
?? Research?Use Disclaimer
This product is intended exclusively for laboratory research use. It is not approved for diagnostic, clinical, therapeutic, or veterinary use. Misuse may lead to serious health and safety risks, and compromise research integrity.
其他信息
| 重量 | 1.1 公斤 |
|---|---|
| 尺寸 | 18 × 16 × 18 厘米 |
相关产品
-
Palbociclib Capsules (Xipeilai) – 125?mg, 21 Capsules Price comparison
Palbociclib Capsules (Research Grade) in 125?mg strength, 21-count bottle. Supplied by Shanghai Chuannuo Pharmaceutical Co., Ltd. For investigational or research applications only—not for human consumption or therapeutic use.
$2.00 -
Limertinib Tablets 80?mg ×?20 – by Osscon Pharma | Research Use Only (3rd?Gen EGFR?TKI)
Limertinib (OuyiXin®) is a third-generation EGFR tyrosine kinase inhibitor (EGFR?TKI) at 80?mg per tablet, 20 tablets per box, from Jiangsu Osscon Pharmaceutical. Approved by China’s NMPA under H20250004, it targets EGFR T790M?mutated non?small cell lung cancer, including patients with brain metastases.
?? For research use only – Not for human consumption or therapeutic use. $1.00 -
Ivodazumab Injection (lvonescimab) – 10?ml per Vial [For Laboratory Research Only]
Ivodazumab (Yidafang®) is a monoclonal antibody developed by Kangfang Pharmaceutical Co., Ltd., approved by China's NMPA (Approval No. S20240020; Drug Code: 86985204000011). Each vial contains 10?ml of the injectable formulation. Strictly for laboratory research use only—not for clinical or human use.
$1.00 -
Irinotecan Hydrochloride Liposome Injection (Du’EnYi®) – 10?mL:43?mg Vial
Irinotecan Hydrochloride Liposome Injection Du’EnYi® is China’s first domestically approved liposome-encapsulated irinotecan injection, equivalent to ONIVYDE®. Each 10?mL vial contains 43?mg irinotecan and is strictly for laboratory research use only—not for clinical or human application.?Please consult the staff for other purposes? $1.00
评价
目前还没有评价